Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Lonza Group

Lonza Group?uq=AFYHfsyn
1897 FOUNDED
PUBLIC STATUS
10K-15K EMPLOYEES
LONN STOCK SYMBOL
32 INVESTMENTS
$315.66 SHARE PRICE (As of Friday Closing)
Description

Producer and supplier of products, services and specialty ingredients for the pharmaceutical and biotechnology industries on a global scale. The company's pharmaceutical products utilize custom chemical manufacturing and fermentation processing and manufactures its products for the life sciences, pharmaceuticals, food processing and agricultural products industries. It also provides product development services to the pharmaceutical and biologic industries, including organic, fine and performance chemicals, custom manufacturing of bio-pharmaceuticals, chemical synthesis capabilities, detection systems and services for the bio-science sector.

Website
Formerly Known As
Lonza AG Electricity Works
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Specialty Chemicals
Environmental Services (B2B)
Stock Exchange
SWX
Primary Office
  • Muenchensteinerstrasse 38
  • 4002 Basel
  • Switzerland

+41 061 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Lonza Group’s full profile, request a free trial.

Lonza Group Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$229.30 - $350.51 $23.1B $312.24 $12.78 294K 74.2M

Lonza Group Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 23,524,364 18,453,134 11,316,366 11,303,231
Revenue 6,050,119 5,185,057 4,192,881 3,954,044
EBITDA 818,836 1,073,576 764,095 745,477
Net Income 929,044 737,385 305,435 288,002
Total Assets 14,037,145 14,156,803 6,701,871 6,321,072
Total Debt 4,228,684 4,358,940 1,825,641 1,960,665
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lonza Group Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Lonza Group‘s full profile, request access.

Request full access to PitchBook

Lonza Group Investments & Acquisitions (32)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (00000000-00 04-Oct-2017 000000000 00000 00 Buildings and Property 00000 000000
00000-00000000000 26-Jul-2017 000000000000000000 Specialty Chemicals 0000 0000
00000000 05-Jul-2017 000000000000000000 00.00 Drug Delivery 0000000 00000000
000000000 00000 17-May-2017 00000 00000 00 Medical Records Systems 000000 00000000000
HansaBioMed Life Sciences 16-May-2017 Merger/Acquisition Clinics/Outpatient Services 000 0000000000
To view this company’s complete investment and acquisition history, request access »

Lonza Group Exits (4)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000000000 02-Dec-2016 00000 00000 00 000 Completed
  • 4 buyers
0000000 00000 14-Feb-2013 00000 00000 00 00.00 Completed
  • 3 buyers
0000000 00000 17-Mar-2010 00000 00000 00 00.00 Completed
  • 00000 00000
Lonza (peptides business in Belgium) 17-Jan-2006 Merger/Acquisition 00000 Completed
To view this company’s complete exits history, request access »

Lonza Group Subsidiaries (11)

Company Name Industry Location Founded
Triangle Research Labs Laboratory Services (Healthcare) Durham, NC 2011
0000000 000 000000 Other Pharmaceuticals and Biotechnology Houston, TX 0000
00000000000 0000 0 Clinics/Outpatient Services Tallinn, Estonia 0000
000000 Biotechnology Münster, Germany 0000
00000 Biotechnology Cologne, Germany 0000
To view this company’s complete subsidiary history, request access »

Lonza Group Executive Team (28)

Name Title Board
Seat
Contact
Info
Richard Ridinger Chief Executive Officer and Member of the Executive Committee
Rodolfo Savitzky Chief Financial Officer and Member of the Executive Committee
Marc Funk Chief Operating Officer of Pharma & Biotech Segment & Member of the Executive Committee
Sven Abend Ph.D Chief Operating Officer of Specialty Ingredients Segent
Uwe Gottschalk Chief Technology Officer

5 Former Executives

You’re viewing 5 of 28 executives. Get the full list »

Lonza Group Board Members (5)

Name Representing Role Since Contact
Info
0000 0000 Lonza Group Chief Operating Officer of Pharma & Biotech Segment & Member of the Executive Committee 000 0000
0000000 00000000 Lonza Group Chief Executive Officer and Member of the Executive Committee 000 0000
0000000 00000000 Lonza Group Chief Financial Officer and Member of the Executive Committee 000 0000

2 Former Board Members

You’re viewing 3 of 5 board members. Get the full list »